Human metabolites and transformation products cyclophosphamide and ifosfamide: analysis, occurrence and formation during abiotic treatments
MetadataShow full item record
This study describes a gas chromatography-mass spectrometry analytical method for the analysis of cytostatic cyclophosphamide (CP), ifosfamide (IF) and their selected metabolites/transformation products (TPs): carboxy-cyclophosphamide (carboxy-CP), keto-cyclophosphamide (keto-CP) and 3-dechloroethyl-ifosfamide/N-dechloroethyl-cyclophosphamide (N-decl-CP) in wastewater (WW). Keto-cyclophosphamide, CP and IF were extracted with Oasis HLB and N-decl-CP and carboxy-CP with Isolute ENV+ cartridges. Analyte derivatization was performed by silylation (metabolites/TPs) and acetylation (CP and IF). The recoveries and LOQs of the developed method were 58, 87 and 103 % and 77.7, 43.7 and 6.7 ng L−1 for carboxy-CP, keto-CP and N-decl-CP, respectively. After validation, the analytical method was applied to hospital WW and influent and effluent samples of a receiving WW treatment plant. In hospital WW, levels up to 2690, 47.0, 13,200, 2100 and 178 ng L−1 were detected for CP, IF, carboxy-CP, N-decl-CP and keto-CP, respectively, while in influent and effluent samples concentrations were below LOQs. The formation of TPs during abiotic treatments was also studied. Liquid chromatography-high-resolution mass spectrometry was used to identify CP and IF TPs in ultrapure water, treated with UV and UV/H2O2. UV treatment produced four CP TPs and four IF TPs, while UV/H2O2 resulted in five CPs and four IF TPs. Besides already known TPs, three novel TPs (CP-TP138a, imino-ifosfamide and IF-TP138) have been tentatively identified. In hospital WW treated by UV/O3/H2O2, none of the target metabolites/TPs resulted above LOQs.
Showing items related by title, author, creator and subject.
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.Mackey, J.; Pienkowski, T.; Crown, J.; Sadeghi, S.; Martin, M.; Chan, Arlene; Saleh, M.; Sehdev, S.; Provencher, L.; Semiglazov, V.; Press, M.; Sauter, G.; Lindsay, M.; Houé, V.; Buyse, M.; Drevot, P.; Hitier, S.; Bensfia, S.; Eiermann, W.; Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 in (2016)BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive ...
Seasonal lake surface water temperature trends reflected by heterocyst glycolipid-based molecular thermometersBauersachs, T.; Rochelmeier, J.; Schwark, Lorenz (2015)It has been demonstrated that the relative distribution of heterocyst glycolipids (HGs) in cultures of N2-fixing heterocystous cyanobacteria is largely controlled by growth temperature, suggesting a potential use of these ...
Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 studyAu, H.; Eiermann, W.; Robert, N.; Pienkowski, T.; Crown, J.; Martin, M.; Pawlicki, M.; Chan, Arlene; Mackey, J.; Glaspy, J.; Pintér, T.; Liu, M.; Fornander, T.; Sehdev, S.; Ferrero, J.; Bée, V.; Santana, M.; Miller, D.; Lalla, D.; Slamon, D. (2013)Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and ...